Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. Issue 2 (1st March 2017)

• Record Type: Journal Article
• Authors: Kosova, Ethan C; Bonaca, Marc P; Dellborg, Mikael; He, Ping; Morais, Joao; Oude Ophuis, Ton; Scirica, Benjamin M; Tendera, Michal; Theroux, Pierre; Braunwald, Eugene; Morrow, David A
• Is Part Of: European heart journal. Volume 6:Issue 2(2017)
• Page Start: 164
• Page End: 172
• Publication Date: 2017-03-01
• Subjects: Vorapaxar -- CABG -- atherothrombosis -- antiplatelet -- bleeding; 616.1205
• DOI: 10.1177/2048872616644910
• Languages: English
• ISSNs: 2048-8726

Abstract

Abstract: Background: Vorapaxar is a first-in-class protease-activated receptor-1 antagonist indicated for the reduction of cardiovascular death, myocardial infarction, and stroke in stable patients with prior atherothrombosis, who have not had a prior stroke or transient ischemic attack. The aims of this study were to investigate: 1) the role of vorapaxar in patients with severe coronary artery disease treated previously with coronary artery bypass grafting (CABG); and 2) safety in patients undergoing CABG while receiving vorapaxar. Methods: TRA 2°P-TIMI 50 was a randomized, double-blinded, placebo-controlled trial of vorapaxar in 26, 449 stable patients with prior atherothrombosis followed for a median of 30 months. We 1) investigated the efficacy of vorapaxar among patients with a history of CABG prior to randomization ( n =2942); and 2) assessed the safety among 367 patients who underwent a new CABG during the trial. Results: Patients with a prior CABG were at higher risk for cardiovascular death, myocardial infarction, or stroke at three years compared with patients without a prior CABG (13.7% vs . 7.8%, p <0.001). Among patients with a prior CABG, vorapaxar significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke (11.9% vs . 15.6%, hazard ratio 0.71, 95% confidence interval 0.58–0.88, p =0.001; number-needed-to-treat = 27). In patients undergoing CABG while receiving vorapaxar, the rate of Thrombolysis in Myocardial Infarction CABG major bleeding was 6.3% vs . 4.1% with placebo (hazard ratio 1.53, 95% confidence interval 0.58–4.01, p =0.39). Conclusions: In patients with a prior CABG, vorapaxar significantly reduced the risk of recurrent major cardiovascular events. In patients undergoing CABG while receiving vorapaxar, bleeding risk appeared similar to that seen in the overall trial population.